226 related articles for article (PubMed ID: 28562377)
21. Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma.
Beuthien-Baumann B; Strumpf A; Zessin J; Bredow J; Kotzerke J
Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1604-9. PubMed ID: 17435996
[TBL] [Abstract][Full Text] [Related]
22. Role of [(18)F]FDG-PET/CT in the detection of occult recurrent medullary thyroid cancer.
Skoura E; Rondogianni P; Alevizaki M; Tzanela M; Tsagarakis S; Piaditis G; Tolis G; Datseris IE
Nucl Med Commun; 2010 Jun; 31(6):567-75. PubMed ID: 20335822
[TBL] [Abstract][Full Text] [Related]
23. Radioguided hepatic resection with
López-Gómez J; Medina-Ornelas S; Salazar-Álvarez MA; Álvarez-Bojórquez M; Zaragoza-Cruz N; Melchor-Ruan J; Álvarez-Cano A
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(4):244-249. PubMed ID: 29754940
[TBL] [Abstract][Full Text] [Related]
24. Clinical impact of
Tuncel M; Kılıçkap S; Süslü N
Ann Nucl Med; 2020 Sep; 34(9):663-674. PubMed ID: 32602032
[TBL] [Abstract][Full Text] [Related]
25. Gallium-68 Dotatate PET/CT is superior to other imaging modalities in the detection of medullary carcinoma of the thyroid in the presence of high serum calcitonin.
Tran K; Khan S; Taghizadehasl M; Palazzo F; Frilling A; Todd JF; Al-Nahhas A
Hell J Nucl Med; 2015; 18(1):19-24. PubMed ID: 25679074
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic value of [
Jamsek J; Hocevar M; Bergant D; Zaletel K; Rep S; Lezaic L
Ann Nucl Med; 2021 Apr; 35(4):429-437. PubMed ID: 33544320
[TBL] [Abstract][Full Text] [Related]
27. 18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation.
Koopmans KP; de Groot JW; Plukker JT; de Vries EG; Kema IP; Sluiter WJ; Jager PL; Links TP
J Nucl Med; 2008 Apr; 49(4):524-31. PubMed ID: 18375923
[TBL] [Abstract][Full Text] [Related]
28. Anti-CEA Pretargeted Immuno-PET Shows Higher Sensitivity Than DOPA PET/CT in Detecting Relapsing Metastatic Medullary Thyroid Carcinoma: Post Hoc Analysis of the iPET-MTC Study.
Bodet-Milin C; Faivre-Chauvet A; Carlier T; Ansquer C; Rauscher A; Frampas E; Toulgoat F; Masson D; Bourgeois M; Cerato E; Rohmer V; Couturier O; Drui D; Goldenberg DM; Sharkey RM; Barbet J; Kraeber-Bodere F
J Nucl Med; 2021 Sep; 62(9):1221-1227. PubMed ID: 33547213
[TBL] [Abstract][Full Text] [Related]
29. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels.
Giraudet AL; Vanel D; Leboulleux S; Aupérin A; Dromain C; Chami L; Ny Tovo N; Lumbroso J; Lassau N; Bonniaud G; Hartl D; Travagli JP; Baudin E; Schlumberger M
J Clin Endocrinol Metab; 2007 Nov; 92(11):4185-90. PubMed ID: 17726071
[TBL] [Abstract][Full Text] [Related]
30. Comparison of 5 Different PET Radiopharmaceuticals for the Detection of Recurrent Medullary Thyroid Carcinoma: A Network Meta-analysis.
Lee SW; Shim SR; Jeong SY; Kim SJ
Clin Nucl Med; 2020 May; 45(5):341-348. PubMed ID: 32049723
[TBL] [Abstract][Full Text] [Related]
31. The role of PET-CT scan with somatostatin analogue labelled with gallium-68 (⁶⁸Ga-DOTA-TATE PET-CT) in diagnosing patients with disseminated medullary thyroid carcinoma (MTC).
Pałyga I; Kowalska A; Gąsior-Perczak D; Tarnawska-Pierścińska M; Słuszniak J; Sygut J; Góźdź S
Endokrynol Pol; 2010; 61(5):507-11. PubMed ID: 21049467
[TBL] [Abstract][Full Text] [Related]
32.
Souteiro P; Gouveia P; Ferreira G; Belo S; Costa C; Carvalho D; Duarte H; Sampaio IL
Endocrine; 2019 May; 64(2):322-329. PubMed ID: 30684230
[TBL] [Abstract][Full Text] [Related]
33. Multimodal imaging with (18)F-FDG-PET/CT and (111)In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma.
De Luca S; Fonti R; Camera L; Salvatore B; Faggiano A; Ciarmiello A; Segreto S; Colao A; Salvatore M; Del Vecchio S
Ann Nucl Med; 2016 Apr; 30(3):234-41. PubMed ID: 26753628
[TBL] [Abstract][Full Text] [Related]
34. Which Is the Optimal Scan Time of 18F-DOPA PET/CT in Patients With Recurrent Medullary Thyroid Carcinoma?: Results From a Dynamic Acquisition Study.
Taralli S; Lorusso M; Capotosti A; Lanni V; Indovina L; Rufini V
Clin Nucl Med; 2020 Mar; 45(3):e134-e140. PubMed ID: 31977485
[TBL] [Abstract][Full Text] [Related]
35. Positron emission tomography (18FDG-PET) in the detection of medullary thyroid carcinoma metastases.
Mucha SA; Kunert-Radek J; Pomorski L
Endokrynol Pol; 2006; 57(4):452-5. PubMed ID: 17006852
[TBL] [Abstract][Full Text] [Related]
36. Calcitonin-Negative Neuroendocrine Tumor of the Thyroid on 68Ga DOTANOC PET-CT.
Tripathy S; Aggrawal S; Subudhi K; Kumar R; Narwal A
Clin Nucl Med; 2019 Sep; 44(9):e546-e547. PubMed ID: 31283604
[TBL] [Abstract][Full Text] [Related]
37. 18F-DOPA PET/CT in Orbital Metastasis From Medullary Thyroid Carcinoma.
Ruiz JB; Orré M; Cazeau AL; Henriques de Figueiredo B; Godbert Y
Clin Nucl Med; 2016 Jun; 41(6):e296-7. PubMed ID: 27055131
[TBL] [Abstract][Full Text] [Related]
38. The role of
Şahin OE; Uslu-Beşli L; Asa S; Sağer S; Sönmezoğlu K
Hell J Nucl Med; 2020; 23(3):321-329. PubMed ID: 33367304
[TBL] [Abstract][Full Text] [Related]
39. Clinical challenges with calcitonin-negative medullary thyroid carcinoma.
Samà MT; Rossetto Giaccherino R; Gallo M; Felicetti F; Maletta F; Bonelli N; Piovesan A; Palestini N; Ghigo E; Arvat E
J Cancer Res Clin Oncol; 2016 Sep; 142(9):2023-9. PubMed ID: 27125958
[TBL] [Abstract][Full Text] [Related]
40. The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT.
Beheshti M; Pöcher S; Vali R; Waldenberger P; Broinger G; Nader M; Kohlfürst S; Pirich C; Dralle H; Langsteger W
Eur Radiol; 2009 Jun; 19(6):1425-34. PubMed ID: 19156423
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
